Mabpharm Ltd banner
M

Mabpharm Ltd
HKEX:2181

Watchlist Manager
Mabpharm Ltd
HKEX:2181
Watchlist
Price: 0.56 HKD Market Closed
Market Cap: HK$2.3B

Mabpharm Ltd
Investor Relations

Mabpharm Ltd. engages in the research, development, and manufacture of monoclonal antibody drugs for the treatment of cancer and autoimmune diseases. The company is headquartered in Taizhou, Jiangsu. The company went IPO on 2019-05-31. The firm's main products include omalizumab (CMAB007), cetuximab (CMAB009) and infliximab (CMAB008). The firm mainly conducts its businesses in China market.

Show more
Loading
2181
Hang Seng (Hong Kong)
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Dr. Hao Wang Ph.D.
Chief Scientist, CEO & Executive Director
No Bio Available
Dr. Weizhu Qian
VP & Executive Director
No Bio Available
Mr. Yunfeng Li
VP, Joint Company Secretary & Executive Director
No Bio Available
Dr. Jing Li
Vice President
No Bio Available
Mr. Ho Yin Tsang B.Com., L.L.B., L.L.M.
Joint Company Secretary
No Bio Available

Contacts

Address
JIANGSU
Taizhou
Block G79, Lujia Road East, Koutai Road West, China Medical City
Contacts
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett